Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
76720.460.7178%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$143.72
-1.09-0.75%
At close: Sep 11, 5:00 PM EST
$143.58
-0.14-0.1%
After Hours: Sep 11, 5:44 PM EST
Dividend: The dividend Ex-Date is tomorrow
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipDividendsCompareOptionsStock Report

Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 8 Quarters

Analyst Consensus — 23 Analysts

19Buy
4Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$137Upside to Avg. PT-4.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026HSBCMorten HerholdtPT RaiseBuy$155→$175
Aug 5, 2026RBC CapitalBrian AbrahamsPT RaiseSector Perform$120→$123
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175

HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.
Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, Snowflake

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $120 to $123.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $155 to $145.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved